Phase 2 N=6 Apremilast for Erythema Multiforme
Erythema Multiforme
Primary: Erythema Multiforme Flares on Medication — 1.7 Number of flares
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=8 Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia
Primary Erythromelalgia · Inherited Erythromelalgia
Primary: Average Daily Use of Cooling for Erythromelalgia-Related Pain in Treatment Period 2 — 0.24; 2.4 cooling uses/day
N/A N=32 Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors
Skin Rash
Primary: Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and…
Phase 2 N=28 Mechlorethamine Induced Contact Dermatitis Avoidance Study
Cutaneous T-cell Lymphoma · Cutaneous T-cell Lymphoma Stage I · Mycosis Fungoides
Primary: Incidence of Moderate to Severe Contact Dermatitis by SCORD Scoring — 16; 11 patients
Phase 2 N=10 EDTA Eye Drops Compared to Abreva for Herpes Simplex Virus Eruptions
Herpes Simplex Oral
Primary: Duration (Days) of Herpes Labialis Outbreak Until Healed — 10.6; 8.25 days
Phase 3 N=184 Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria
EPP · XLP
Primary: Change From Baseline in Average Daily Sunlight Exposure Time (Minutes) to First Prodromal Symptom (Burning, Tingling, Itching, or Stinging) Associated With Sunlight…
Phase 2 N=102 Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria
Erythropoietic Protoporphyria (EPP)
Primary: Change From Baseline in Average Daily Time (Minutes) to First Prodromal Symptom Associated With Sunlight Exposure Between Hour Post Sunrise and 1 Hour Pre-Sunset at Week…
Phase 3 N=100 Multicentre Phase III Erythropoietic Protoporphyria Study
Erythropoietic Protoporphyria
Primary: Cumulative Number of Days of Phototoxic Reactions (Study Efficacy Population) — 39; 45; 129; 179 Days
Phase 2 N=8 Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis
Dermatomyositis, Adult Type
Primary: The Primary Endpoint Analysis Would be Overall Response Rate Measured by the Number of Participants Experiencing at Least 4 Points Decrease in CDASI Activity Score at 3…
Phase 3 N=135 A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)
Pemphigus Vulgaris
Primary: Percentage of Participants (Excluding Telemedicine [TM] Participants) Who Achieved Sustained Complete Remission, Evaluated by the Pemphigus Disease Area Index (PDAI)…
Phase 2 N=23 Activity of Valomaciclovir in Infectious Mononucleosis Due to Primary Epstein-Barr Virus Infection
Infectious Mononucleosis
Primary: Number of Participants With Improvement in Clinical Symptoms and Reductions in Viral Burden From Baseline — 12; 11 participants
Phase 3 N=93 Phase III Confirmatory Study in Erythropoietic Protoporphyria
Erythropoietic Protoporphyria
Primary: Duration of Direct Sunlight Exposure Between 10:00 and 18:00 Hours on Days When no Pain Was Experienced (Pain Score of 0). — 69.4; 40.8 hours
N/A N=104 Study of Inter- and Intra-rater Reliability of the Clinician Erythema Assessment Scale
Erythema · Rosacea
Primary: Inter-rater Reliability of the Clinician Erythema Assessment (CEA) Scale — 0.908 Kendall's W
Phase 3 N=201 A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.
Non-Small Cell Lung Cancer
Primary: Percentage of Participants Who Develop Skin Rash — 60.0; 69.2; 73.1 percentage of participants — p=0.481
Phase 3 N=143 Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation
Invasive Breast Cancer
Primary: Percentage of Participants With Moist Desquamation — 66.7; 43.8 % of participants w/moist desquamation
N/A N=306 Duration of Antibiotic Treatment of Erythema Migrans
Erythema Chronicum Migrans
Primary: Objective Sequelae and Post-treatment Subjective New or Increased Symptoms (NOIS)in Patients Treated for Erythema Migrans With Doxycycline for 10 or 15 Days. — 79; 85…
Phase 2 N=21 Pimecrolimus Cream for Oral Lichen Planus
Oral Lichen Planus
Primary: The Primary Efficacy Variable Was the Change in the Investigator's Global Assessment of the Overall Severity of Disease From Baseline to Week 6. — 2.4; 2.45; 1.6; 2.27…
Phase 2 N=66 Mepo for Eosinophilic Esophagitis (EoE) Study
EoE · Eosinophilic Esophagitis
Primary: Mean Change in Dysphagia Score — 15.4; 8.3 score on a scale — p=0.14
Phase 2 N=260 Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides
Mycosis Fungoides
Primary: Ratio of Response Rates Based on CAILS — 76; 62 percentage of participants
Phase 1 N=36 Immune Response and General Immune Health in Subjects Infected With Herpes Simplex Virus Type 1 (HSV-1)
HSV · Herpes Labialis
Primary: Ratio of Absolute Gene Expression of IFNG and IL5 in PBMCs Between 8 Weeks and Baseline — 10.073; 11.380; 10.711; 11.431 q-RT-PCR crossing threshold cycle (Ct)
Phase 2 N=150 Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer
Rash
Primary: Overall Incidence of Rash — 84; 84; 82 percentage of participants — p=0.8769
Phase 2 N=5 Evaluation Of The Efficacy And Safety Of Single Doses Of PF-05089771 In Patients With Primary (Inherited) Erythromelalgia
Inherited Erythromelalgia
Primary: Average Pain Intensity Numerical Rating Scale (PI-NRS) Score - From 0 to 4 Hours Post-dose — 2.08; 2.73; 1.95; 2.04 Units on a scale